Disclosed is the use of cyclobenzaprine in the manufacture of a medicament for treating depression, said medicament comprising cyclobenzaprine in a therapeutically effective amount and a therapeutically effective carrier, wherein the medicament is formulated to be administered at bedtime, and wherein the medicament is formulated for sequential or concurrent administration with an antidepressant drug (such as an alpha-1-adrenergic receptor antagonist (e.g. prazosin), a beta-adrenergic antagonist, an anticonvulsant (e.g. carbamazepine, gabapentin, lamotrigine, oxcarbazepine, pregabalin, tiagabine, topiramate, or valproate), a selective serotonin reuptake inhibitor (e.g. escitalopram) and a serotonin-norepinephrine reuptake inhibitor). Also disclosed is the use, wherein an amount of cyclobenzaprine is less than 2.5 mg/day, and preferably formulated for sublingual administration.
